Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Medchemcomm|November 2, 2019
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinityAna R N Santos, Helen M Sheldrake, Ali I M Ibrahim, et al.
Bioorganic & Medicinal Chemistry|May 1, 2021
Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compoundsNatalia Ortuzar, Kersti Karu, Daniela Presa, et al.
Nature Communications|March 24, 2026
RNA functional modulation by Mitoxantrone via RNA structural ensemble repartitioningChundan Zhang, Ivana Borovská, Teona Iobashvili, et al.
European Journal of Medicinal Chemistry|September 8, 2017
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approachAgnese C Pippione, Alessandro Giraudo, Davide Bonanni, et al.
Journal of Medicinal Chemistry|February 25, 2022
Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate CancerAli I M Ibrahim, Elisabet Batlle, Smarakan Sneha, et al.
European Journal of Medicinal Chemistry|April 21, 2022
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffoldAgnese Chiara Pippione, Zühal Kilic-Kurt, Sandra Kovachka, et al.
Molecular Cancer Therapeutics|October 4, 2012
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladderMark Sutherland, Jason H Gill, Paul M Loadman, et al.
Scientific Reports|September 24, 2021
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancerDaniela Presa, Syed A Khurram, Amir Z A Zubir, et al.
Biochemical Pharmacology|March 6, 2012
Minor structural modifications to alchemix influence mechanism of action and pharmacological activityQasem M A Abdallah, Roger M Phillips, Fredrik Johansson, et al.
Journal of Medicinal Chemistry|July 13, 2013
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activityHelen M Sheldrake, Sandra Travica, Inger Johansson, et al.
Pageof 6